{"id":"W3012570191","doi":"10.1016/s2352-3026(20)30070-3","title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Surgery; Clinical trial; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003130374,0.0004035407,0.002005074,0.0001016417,0.0002308057,0.00008381738,0.000687482,0.0002192819,0.0002453143],"category_scores_gemma":[0.001773155,0.0002453966,0.00007095658,0.0004429582,0.0002834851,0.0001597715,0.0003266649,0.0007823974,0.0001795095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001939527,"about_ca_system_score_gemma":0.0004359966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003902277,"about_ca_topic_score_gemma":0.001565231,"domain_scores_codex":[0.9966985,0.0004838539,0.0006520591,0.0006718728,0.0005100529,0.0009836688],"domain_scores_gemma":[0.9971873,0.00111879,0.0002735598,0.0008047686,0.0001658129,0.0004497299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9638271,0.004685221,0.01366731,0.0001681335,0.0004315956,0.008111784,0.0009775333,0.000002564609,0.000117444,0.00001804067,0.0008838661,0.007109374],"study_design_scores_gemma":[0.9666863,0.02304518,0.005857144,0.0001151788,0.0002341895,0.0002091319,0.0001425668,0.001948858,0.0001568684,0.000007006657,0.001305348,0.0002921962],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880552,0.00009970782,0.00003539072,0.002003402,0.0003508226,0.008337151,0.0000933162,0.00009138665,0.0009336093],"genre_scores_gemma":[0.9972318,0.00008559383,0.001017861,0.0005853205,0.000262134,0.0004357457,0.0002157009,0.00006569221,0.0001000826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01835996,"threshold_uncertainty_score":0.9999998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08514856475611958,"score_gpt":0.3579203474354993,"score_spread":0.2727717826793797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}